Holen Sie sich die Stockscreener-App
3.15
1.61%
0.05
Vorhandelsmarkt:
3.15
Imunon Inc Aktie (IMNN) Neueste Nachrichten
Is Imunon Inc stock a good pick for beginnersWeekly Trade Report & High Return Trade Opportunity Guides - baoquankhu1.vn
Imunon (IMNN) Short Interest & Short Float | Updated Apr 2026 - MarketBeat
Imunon, Inc. (NASDAQ:IMNN) Q4 2025 Earnings Call Transcript - MSN
Guidance Update: Can Imunon Inc reach all time highs this year2026 Stock Rankings & AI Forecast Swing Trade Picks - baoquankhu1.vn
Institution Moves: Can Imunon Inc sustain earnings growth2026 Outlook & AI Forecasted Stock Moves - baoquankhu1.vn
Investment Review: Can Imunon Inc continue delivering strong returns2026 Summary & Precise Entry and Exit Recommendations - baoquankhu1.vn
HC Wainwright Brokers Increase Earnings Estimates for Imunon - Defense World
IMNN Technical Analysis & Stock Price Forecast - Intellectia AI
Imunon Earnings Call: Strong Data, Tight Cash Runway - TipRanks
Imunon Q4 Earnings Call Highlights - Defense World
IMNN PE Ratio & Valuation, Is IMNN Overvalued - Intellectia AI
Imunon, Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
IMUNON reports final Phase 2 data for ovarian cancer treatment By Investing.com - Investing.com South Africa
Imunon targets ~80 OVATION 3 patients in the next 12 months as cash runway extends into H2 2026 - MSN
Imunon Inc (IMNN) Q4 2025 Earnings Call Highlights: Strategic Ad - GuruFocus
IMUNON 2025 Financial Review - AlphaStreet
IMUNON Reports 2025 Financial Results and Highlights Breakthrough Phase 3 Progress for IMNN-001 in Advanced Ovarian Cancer - Minichart
Imunon Inc’s 2025 Q4 Earnings Call: FDA Submission Delays, Shifting Trial Timelines, and Enrollment Discrepancies Highlight Contradictions - Bitget
IMUNON INC (NASDAQ:IMNN) Reports Q4 2025 Results with Focus on Phase 3 Progress for IMNN-001 - ChartMill
Earnings call transcript: Imunon Inc’s Q4 2025 shows cost discipline, clinical progress - Investing.com
IMUNON ($IMNN) Releases Q4 2025 Earnings - Quiver Quantitative
IMUNON, INC. 2025 Annual Report: Pipeline, Clinical Trials, Financials & Business Strategy Overview - Minichart
Imunon (NASDAQ: IMNN) posts strong IMNN-001 survival data but flags going concern risk - Stock Titan
Imunon Reports 2025 Financial Results And Provides Business Update - TradingView — Track All Markets
IMUNON Reports 2025 Financial Results and Provides Business Update Highlighting Significant Progress with Pivotal Phase 3 Study - The Manila Times
Imunon reports $14.5M net loss and $8.8M cash at year-end; highlights Phase 3 progress - TradingView — Track All Markets
Imunon, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
IMUNON (IMNN) highlights 2025 loss reduction and strong IMNN-001 survival data - Stock Titan
IMUNON Reports 2025 Financial Results and Provides Business - GlobeNewswire
Imunon Inc (IMNN) Q4 2025 Earnings Call Highlights: Strategic Advances and Financial Management By GuruFocus - Investing.com Canada
Imunon Scheduled to Announce Q4 Earnings on March 30 - Intellectia AI
Inflation Data: Can Imunon Inc sustain earnings growthPortfolio Profit Report & Verified Technical Trade Signals - baoquankhu1.vn
IMUNON reports improved survival data for ovarian cancer therapy By Investing.com - Investing.com South Africa
Imunon Inc. Expands Market Footprint Amid Strategic Deals and Financial Challenges - timothysykes.com
IMUNON's IMNN-001 Shows Continued Gains In Overall Survival In Phase 2 Ovarian Cancer Trial - RTTNews
Imunon (IMNN) Reports Promising Phase 2 OVATION 2 Trial Results - GuruFocus
IMUNON reports improved survival data for ovarian cancer therapy - investing.com
With PARP therapy, women on IMUNON lived 24.2 months longer - stocktitan.net
Aug Closing: Is Imunon Inc stock a good pick for beginners2026 Big Picture & Real-Time Volume Analysis Alerts - baoquankhu1.vn
IMUNON to Hold 2025 Financial Results and Business Update Conference Call on Tuesday, March 31, 2026 - marketscreener.com
IMUNON, Inc. Files Form 8-K with NASDAQ Listing and Company Details for March 2026 - Minichart
Imunon Expands At-The-Market Equity Offering Capacity - TipRanks
Imunon registers additional $7 million in shares under at-the-market offering - Investing.com India
Imunon registers additional $7M, raising ATM capacity to $17M - TradingView
Imunon (NASDAQ: IMNN) boosts at-the-market stock program to $17M - Stock Titan
Imunon (NASDAQ: IMNN) ups ATM program by $7M to $17M capacity - Stock Titan
S P Trends: What is the next catalyst for Imunon Inc2026 Weekly Recap & Weekly Watchlist for Hot Stocks - baoquankhu1.vn
Dividend Watch: Will Imunon Inc outperform tech stocksQuarterly Profit Report & Accurate Entry and Exit Point Alerts - baoquankhu1.vn
Imunon Q2 2025 Earnings Preview - MSN
Imunon declares $0.15 dividend - MSN
Signal Recap: Will Imunon Inc outperform tech stocksGold Moves & Low Risk Entry Point Guides - baoquankhu1.vn
Market Overview: Is Imunon Inc a defensive stock2025 Key Highlights & Smart Swing Trading Techniques - baoquankhu1.vn
IMNN Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
IMNN SEC FilingsImunon Inc 10-K, 10-Q, 8-K Forms - Stock Titan
2.69%
0.25%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):